- Home
- UWMC vs KURA Comparison
UWMC vs KURA Comparison
Compare UWMC & KURA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- UWMC
- KURA
- Stock Information
- Founded
- UWMC 1986
- KURA 2014
- Country
- UWMC United States
- KURA United States
- Employees
- UWMC N/A
- KURA N/A
- Industry
- UWMC Finance: Consumer Services
- KURA Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- UWMC Finance
- KURA Health Care
- Exchange
- UWMC Nasdaq
- KURA Nasdaq
- Market Cap
- UWMC 971.2M
- KURA 793.2M
- IPO Year
- UWMC N/A
- KURA N/A
- Fundamental
- Price
- UWMC $5.89
- KURA $9.01
- Analyst Decision
- UWMC Hold
- KURA Strong Buy
- Analyst Count
- UWMC 8
- KURA 10
- Target Price
- UWMC $7.41
- KURA $30.13
- AVG Volume (30 Days)
- UWMC 3.1M
- KURA 2.5M
- Earning Date
- UWMC 11-07-2024
- KURA 11-07-2024
- Dividend Yield
- UWMC 6.80%
- KURA N/A
- EPS Growth
- UWMC N/A
- KURA N/A
- EPS
- UWMC N/A
- KURA N/A
- Revenue
- UWMC $2,727,467,000.00
- KURA N/A
- Revenue This Year
- UWMC $2.19
- KURA N/A
- Revenue Next Year
- UWMC $26.43
- KURA $106.66
- P/E Ratio
- UWMC N/A
- KURA N/A
- Revenue Growth
- UWMC 29.95
- KURA N/A
- 52 Week Low
- UWMC $5.44
- KURA $8.85
- 52 Week High
- UWMC $9.74
- KURA $24.17
- Technical
- Relative Strength Index (RSI)
- UWMC 40.82
- KURA 22.05
- Support Level
- UWMC $5.44
- KURA $8.85
- Resistance Level
- UWMC $6.48
- KURA $10.02
- Average True Range (ATR)
- UWMC 0.27
- KURA 0.48
- MACD
- UWMC -0.04
- KURA 0.08
- Stochastic Oscillator
- UWMC 37.71
- KURA 6.30
About UWMC UWM Holdings Corporation
UWM Holdings Corp engages in the origination, sale and servicing of residential mortgage loans. The company provides independent mortgage advisors across the states and the district of Columbia.
About KURA Kura Oncology Inc.
Kura Oncology Inc is a clinical-stage biopharmaceutical company, that engages in discovering and developing therapeutics for the treatment of solid tumors and blood cancers. It focuses on the development of small-molecule product candidates that target cell signaling pathways to drive the progression of various cancers. The company has a product candidate, Tipifarnib, which is a farnesyl transferase inhibitor, in both solid tumors and blood cancers. Geographically operation of the group is carried through the United States.